Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL PIRAE PHARMA : revenue, balance sheet and financial ratios

SPFPL PIRAE PHARMA is a French company founded 7 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in NARBONNE (11100), this company of category PME shows in 2025 a net income negative of -17 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL PIRAE PHARMA (SIREN 852408533)
Indicator 2025 2024 2023 2022 2021 2020
Revenue N/C N/C N/C N/C N/C N/C
Net income -16 886 € -19 908 € 282 153 € 132 833 € 125 414 € -17 318 €
EBITDA -8 863 € -8 866 € -9 375 € -9 399 € -8 368 € -9 267 €
Net margin N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SPFPL PIRAE PHARMA records a net loss of 17 k€. This deficit will reduce equity on the balance sheet.

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-8 863 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-8 863 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-16 886 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 49%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 67%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

49.473%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

66.902%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-73.142

Solvency indicators evolution
SPFPL PIRAE PHARMA

Sector positioning

Debt ratio
49.47 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average

In 2025, the debt ratio of SPFPL PIRAE PHARMA (49.47) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
66.9% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good

In 2025, the financial autonomy of SPFPL PIRAE PHARMA (66.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
-73.14 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.77 years
Q3: 6.12 years
Excellent -45 pts over 3 years

In 2025, the repayment capacity of SPFPL PIRAE PHARMA (-73.14) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-65.644

Liquidity indicators evolution
SPFPL PIRAE PHARMA

Sector positioning

Interest coverage
-65.64x 2025
2023
2024
2025
Q1: -191.54x
Med: -25.42x
Q3: 0.0x
Average +12 pts over 3 years

In 2025, the interest coverage of SPFPL PIRAE PHARMA (-65.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL PIRAE PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL PIRAE PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL PIRAE PHARMA

What is the revenue of SPFPL PIRAE PHARMA ?

The revenue of SPFPL PIRAE PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL PIRAE PHARMA profitable?

SPFPL PIRAE PHARMA recorded a net loss in 2025.

Where is the headquarters of SPFPL PIRAE PHARMA ?

The headquarters of SPFPL PIRAE PHARMA is located in NARBONNE (11100), in the department Aude.

Where to find the tax return of SPFPL PIRAE PHARMA ?

The tax return of SPFPL PIRAE PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL PIRAE PHARMA operate?

SPFPL PIRAE PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.